It is estimated that not less than USD 28 billion are spent each year in the USA alone on irreproducible pre-clinical research, which is not only a fundamental loss of investment and resources but also a strong inhibitor of efficiency for upstream processes regarding the translation towards clinical applications and therapies. The issues and cost of irreproducibility has mainly been published on pre-clinical research. In contrast to pre-clinical research, test material is often being transferred into humans in clinical research. To protect treated human subjects and guarantee a defined quality standard in the field of clinical research, the manufacturing and processing infrastructures have to strictly follow and adhere to certain (inter-)national quality standards. It is assumed and suggested by the authors that by an implementation of certain quality standards within the area of pre-clinical research, billions of USD might be saved and the translation phase of promising pre-clinical results towards clinical applications may substantially be improved. In this review, we discuss how an implementation of a quality assurance (QA) management system might positively improve sample quality and sustainability within pre-clinically focused biobank infrastructures. Biobanks are frequently positioned at the very beginning of the biomedical research value chain, and, since almost every research material has been stored in a biobank during the investigated life cycle, biobanking seems to be of substantial importance from this perspective. The role model of a QA-regulated biobank structure can be found in biobanks within the context of clinical research organizations such as in regenerative medicine clusters.

Keywords:
Translational medicine, Regenerative medicine, Biobank, Pre-clinical research, Clinical research, QA
1.
Westfall JM, Mold J, Fagnan L: Practice-based research - ‘Blue Highways' on the NIH roadmap. JAMA 2007;297:403-406.
2.
BSI: PAS 84:2012 Cell therapy and regenerative medicine. Glossary. http://shop.bsigroup com/Browse-by-Sector/Healthcare/PAS-84/ (last accessed August 23, 2016).
3.
Mason C, Dunnill P: A brief definition of regenerative medicine. Regen Med 2008;3:1-5.
4.
National Institute of Biomedical Imaging and Bioengineering: Tissue Engineering and Regenerative Medicine. http://www nibib.nih.gov/science-education/science-topics/tissue-engineering-and-regenerative-medicine (last accessed August 23, 2016).
5.
Terzic A, Pfenning MA, Gores GJ, Harper CM Jr: regenerative medicine build-out. Stem Cells Transl Med 2015;4:1373-1379.
6.
Hewitt R, Watson PH: Defining biobank. Biopreserv Biobank 2013;11:309-315.
7.
OECD: Creation and Governance of Human Genetic Databases. 2006. www.oecd.org/sti/biotech/creationandgovernanceofhumangeneticresearchdatabases.htm (last accessed August 23, 2106)
8.
Watson PH, Barnes RO: A proposed schema for classifying human research biobanks. Biopreserv Biobank 2011;9:327-333.
9.
Yuille M: Brave New World. Biopreserv Biobank 2015;13:433-434.
10.
Vaught J, Rogers J, Myers K, Lim MD, Lockhart N, Moore H, Sawyer S, Furman JL, Compton C: An NCI perspective on creating sustainable biospecimen resources. J Natl Cancer Inst Monogr 2011;42:1-7.
11.
Brevignon-Dodin L: Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU. Biomed Mater Eng 2010;20:121-126.
12.
Bowen A, Casadevall A: Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research. Proc Natl Acad Sci U S A 2015;112:11335-11340.
13.
Freedman LP, Cockburn IM, Simcoe TS: The economics of reproducibility in preclinical research. PLoS Biol 2015;13:e1002165.
14.
Begley CG, Ellis LM: Drug development: raise standards for preclinical cancer research. Nature 2012;483:531-533.
15.
Prinz F, Schlange T, Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011;10:712.
16.
Hughes SE, Barnes RO, Watson P: Biospecimen use in cancer research over two decades. Biopres Biobank 2010; 8:89-97.
17.
Castillo-Pelayo T, Babinszky S, LeBlanc J, Watson PH: The importance of biobanking in cancer research. Biopreserv Biobank 2015;13:172-177.
18.
Simera I, Moher D, Hirst A, Hoey J, Schulz KF, Altman DG: Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network. BMC Med 2010;8:24.
19.
Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hainaut P, Hayes DF, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J: Biospecimen reporting for improved study quality (BRISQ). Biopreserv Biobank 2011;9:57-70.
20.
Simeon-Dubach D, Watson P: Biobanking 3.0: evidence based and customer focused biobanking. Clin Biochem 2014;47:300-308.
21.
Downey P, Peakman TC: Design and implementation of a high-throughput biological sample processing facility using modern manufacturing principles. Int J Epidemiol 2008;37(suppl 1):i46-i50.
22.
Berman S, Wexelblat S, Pool T, Moore T, Shea K: Statistical methods for determining freezer maintenance requirements. Biopreserv Biobank 2012;10:216-QAC18.
23.
French National Standards: NF S 96-900 Certification of Biological Resource Centres. www.p3gobservatory.org/download/projet+norme+Biobanque+Eng pdf (last accessed August 23, 2016).
24.
International Standard Organisation (ISO): ISO 9001:2015 Quality Management Systems - Requirements. www.iso.org/iso/catalogue_detail?csnumber=62085 (last accessed August 23, 2016).
25.
International Standard Organisation (ISO): ISO 15189:2012 Medical Laboratories - Requirement for Quality and Competence. www.iso.org/iso/catalogue_detail? csnumber=56115 (last accessed August 23, 2016).
26.
International Standard Organisation (ISO): ISO/IEC 17025:2005 General Requirements for the Competence of Testing and Calibration Laboratories. www.iso.org/iso/catalogue_detail htm?csnumber=39883 (last accessed August 23, 2016).
27.
International Standard Organisation (ISO): ISO/TC 276 Biotechnology. www.iso.org/iso/home/standards_development/list_of_iso_technical_committees/iso_technical_committee htm?commid=4514241 (last accessed August 23, 2016).
28.
Furuta K, Schacter B: Report on Status of ISO276/WG2 on biobanks and bioresources: international standards for biobanking. Biopreserv Biobank 2015;13:452-453.
29.
ISBER: 2012 best practices for repositories: collection, storage, retrieval, and distribution of biological material for research. Biopreserv Biobank 2012;10:79-161.
30.
Kofanova OA, Mathieson W, Thomas GA, Betsou F: DNA fingerprinting: a quality control case study for human biospecimen authentication. Biopreserv Biobank 2014;12:151-153.
31.
Betsou F: Biospecimen processing method validation. Biopreserv Biobank 2015;13:69.
32.
Geddes TJ, Ketelsen BE, Ahmed S, Pruetz BL, Fortier LE: Utilizing in-house resources to correct sample mixups in a medium throughput biorepository: a case study. Biopreserv Biobank 2016;14:75-80.
33.
Parrish RS, Garafalo AV, Ndifor V, Goetz KE, Reeves MJ, Yim A, Cooper RC, Iano-Fletcher J, Wang X, Tumminia SJ: Sample confirmation testing: a short tandem repeat-based quality assurance and quality control procedure for the eyeGENE biorepository. Biopreserv Biobank 2016;14:149-155.
34.
Carithers LJ, Ardlie K, Barcus M, Branton PA, Britton A, Buia SA, Compton CC, DeLuca DS, Peter-Demchok J, Gelfand ET, Guan P, Korzeniewski GE, Lockhart NC, Rabiner CA, Rao AK, Robinson KL, Roche NV, Sawyer SJ, Segre AV, Shive CE, Smith AM, Sobin LH, Undale AH, Valentino KM, Vaught J, Young TR, Moore HM: A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv Biobank 2015;13:311-319.
35.
Le PC, Kobel M, de LM, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piche A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM: Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. Biopreserv Biobank 2013;11:83-93.
36.
Ahmad-Nejad P, Duda A, Sucker A, Werner M, Bronsert P, Stickeler E, Reifenberger G, Malzkorn B, Oberlander M, Habermann JK, Bruch HP, Linnebacher M, Schadendorf D, Neumaier M: Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Clin Chem Lab Med 2015;53:1927-1934.
37.
Betsou F, Sobel ME: The ISBER biorepository proficiency testing program: two successful years already, and new features to come. Biopreserv Biobank 2013;11:255-256.
38.
ISBER: International Society of Biological and Environmental Repositories. www.isber.org (last accessed August 23, 2016)..
39.
Stephens N, Dimond R: Closure of a human tissue biobank: individual, institutional, and field expectations during cycles of promise and disappointment. New Genet Soc 2015;34:417-436.
40.
Baker TP, Mateczun JM, Rice CL: Military institute: US pathology centre units will live on. Nature 2011;477:407.
41.
Galbraith JW: Sustainability in the modern biorepository environment from the perspective of the tissue procurement core at the University of Iowa. Biopreserv Biobank 2015;13:430-432.
42.
Uzarski D, Burke J, Turner B, Vroom J, Short N: A plan for academic biobank solvency-leveraging resources and applying business processes to improve sustainability. Clin Transl Sci 2015;8:553-557.
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.